1. Cannabis Legalization Does Not Influence Patient Compliance with Opioid Therapy 
Sheng-Ying Lo, PhD, Gabrielle N. Winston-McPherson, PhD, Amy J. Starosta, PhD, Mark D. Sullivan, MD, Geoffrey S. Baird, MD, PhD, Andrew N. Hoofnagle, MD, PhD, Dina N. Greene, PhD 
The American Journal of Medicine 
Volume 132, Issue 3, Pages (March 2019)
DOI: /j.amjmed
Copyright © 2018 Elsevier Inc. Terms and Conditions

2. Figure 1
An overview of the study design and testing panel results are shown. The individual number of results is represented by N, and the value in parenthesis is the number of unique patients. Cannabinoids screening results are represented as tetrahydrocannabinol positive and tetrahydrocannabinol negative. THC = tetrahydrocannabinol.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © 2018 Elsevier Inc. Terms and Conditions

3. Figure 2
For all panels, results obtained in the pre- and post-marijuana legalization periods are shown. Values within the bars are percentages, and N represents the number of individual results. Results were classified by treatment location (cancer/sickle cell, pain, or primary/secondary clinics). Panel (A) indicates cannabinoid screening results, (B) overall compliance rate, and (C) results stratified by positive or negative cannabinoids screen.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © 2018 Elsevier Inc. Terms and Conditions

4. Figure 3
For all panels, results obtained in the pre- and post-marijuana legalization periods are shown. Values within the bars are percentages. N represents the number of individual results. Results were classified based on sex (male or female). Panel (A) indicates cannabinoid screening results, (B) overall compliance rate, and (C) results stratified by positive or negative cannabinoids screen.
The American Journal of Medicine  , DOI: ( /j.amjmed )
Copyright © 2018 Elsevier Inc. Terms and Conditions